AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05552742 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conservative rehabilitation
Description: The conservative rehabilitation program includes a patient-specific conservative exercise program comprising exercises that strengthen the paralyzed side, increase joint range of motion and strengthen muscles, stretch spastic muscles, and ensure balance rehabilitation that enhances balance performance and coordination. The patients in both groups received conservative rehabilitation program for 8 weeks, 4 days a week for 1 h.
Study NCT05552742 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Balance Training
Description: Virtual balance training program using the Thera-Trainer Balo device was applied 4 times a week for a total of 8 weeks, and each session lasted for 20 min. The center of mass of each patient was determined using sensors and displayed on the screen. The patients were encouraged to move their mass by swiping in all directions via the apple picking game displayed on the screen
Study NCT05361135 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: Enhanced imaging with PET/CT
Study NCT05885061 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal cord stimulation turned on (suggestions: off)
Description: Spinal cord stimulation turned on with verbal suggestions of treatment off
Study NCT05885061 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Spinal cord stimulation turned off (suggestions: on)
Description: Spinal cord stimulation turned off with verbal suggestions of treatment on
Study NCT05885061 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal cord stimulation turned on with suggestions (suggestions on)
Description: Spinal cord stimulation turned on with verbal suggestions of treatment on
Study NCT05269953 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active stimulation
Description: Participants assigned to the active stimulation arm will receive rhythmic MNS 2 minutes on and 1 minute off for 15 minutes. The strength of the stimulation will be set to 120% the intensity needed to produce a visible contraction within the thenar muscle.
Study NCT05269953 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Participants assigned to the sham stimulation arm will receive rhythmic MNS 2 minutes on and 1 minute off for 15 minutes. The strength of the stimulation will be set to 50% the intensity needed to produce a visible contraction within the thenar muscle.
Study NCT05105776 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Galvanic stimulation
Description: Galvanic stimulation during physiotherapy sessions
Study NCT05350046 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ear-worn prototype devices
Description: Hearing instrument including sensors to track movement and estimations of biological information.
Study NCT04922177 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Indirect ceramic restoration
Description: Indirect ceramic restoration using an optical impression.
Study NCT04875572 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Analgesia Nociception Index (ANI) Monitor
Description: The ANI monitor produces an objective measure of parasympathetic tone through non-invasive electrodes placed on the patient's chest. The patient's standard of care is not affected, and the anesthetist is blinded to the monitor, so as not to affect their anesthetic practice.
Study NCT05098366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: 0.1mg/kg (max 5mg) of IV furosemide
Study NCT05098366 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 20mL/kg (max 1000mL) normal saline bolus plus a normal saline flush
Study NCT05469620 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meal
Description: Either a meal kit low in sodium, potassium, and phosphorus; or a meal kit low in sodium only is provided based on predefined logic. Meal kits are delivered in bulk twice a week, meant to replace one meal a day.
Study NCT05469620 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Leaflet or video education materials on seven nutrition-related topics are provided, based on predefined logic. Materials are sent throughout the week, via SMS links.
Study NCT06015919 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dash diet
Description: * Group (A): It will include 15 post-menopausal women who will be treated by DASH diet and anti-hypertensive drugs.~* Group (B): It will include 15 post-menopausal women who will be treated by acupuncture and anti-hypertensive drugs.~* Group (C): It will include 15 post-menopausal women who will be treated by DASH diet, acupuncture and anti-hypertensive drugs.
Study NCT06015919 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: acupuncture
Study NCT04922177 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct restoration
Description: Restoration using a Glass Ionomer Cement
Study NCT05116826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: 500 mg Twice Daily for 7 days
Study NCT05787743 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Facial cream with 2% palm tocotrienols extract
Description: Apply on the face twice a day
Study NCT05787743 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Base cream
Description: Apply on the face twice a day
Study NCT05186051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZYIL1 capsule
Description: NLRP3 inflammasome inhibitor
Study NCT05122377 — intervention group
Intervention type: DRUG
Intervention: 3M GnRHa
Description: This was a real world, observational study of adjuvant endocrine therapy with GnRHa for OFS in postoperative, premenopausal women with endocrine responsive breast cancer. Patients will receive treatment per GnRHa commercial label instruction: leuprorelin, goserelin, leuprorelin from local like: acetate microspheres sustained for injection(boennuokang), leuprorelin acetate microspheres for injection(beiyi).
Study NCT05122377 — intervention group
Intervention type: DRUG
Intervention: 1M GnRHa
Description: This was a real world, observational study of adjuvant endocrine therapy with GnRHa for OFS in postoperative, premenopausal women with endocrine responsive breast cancer. Patients will receive treatment per GnRHa commercial label instruction: leuprorelin, goserelin, leuprorelin from local like: acetate microspheres sustained for injection(boennuokang), leuprorelin acetate microspheres for injection(beiyi).
Study NCT05977101 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MY-586 SARS-CoV-2 Neutralizing Antibody nasal spray
Description: Patients who met the inclusion and exclusion criteria were randomly assigned to one of three different cohorts. Subjects in each cohort were randomly assigned in a ratio of 5:1 to two parallel dosing groups, one of which served as the control group. Each cohort was given either an experimental drug or a placebo nasal spray at different doses and intervals, and blood was collected on an empty stomach before the first dose, and left nasal swabs and throat swabs were collected for immunotoxicity and drug concentration testing.
Study NCT05977101 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: MY-586 SARS-CoV-2 Neutralization Antibody nasal excipient
Description: Patients who met the inclusion and exclusion criteria were randomly assigned to one of three different cohorts. Subjects in each cohort were randomly assigned in a ratio of 5:1 to two parallel dosing groups, one of which served as the control group. Each cohort was given either an experimental drug or a placebo nasal spray at different doses and intervals, and blood was collected on an empty stomach before the first dose, and left nasal swabs and throat swabs were collected for immunotoxicity and drug concentration testing.
Study NCT04910581 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: Single 30-minutes session of 1Hz rTMS applied over the left laryngeal motor cortex
Study NCT04910581 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham stimulation
Description: Single 30-minutes session of sham stimulation applied over the left laryngeal motor cortex
Study NCT05784402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide J
Description: Participants will receive oral semglutide J at dose level 1 and 3 in treatment sequence A and C; and at dose level 2 and 4 in treatment sequence B and D.
Study NCT05784402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide C
Description: Participants will receive oral semglutide C in treatment sequence A and B; and at semglutide C at 2x dose level in treatment sequence C and D.
Study NCT04954417 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Radiological scanning
Description: The collected specimens subject to normalized Micro-CT and MSCT image acquisition, image reconstruction using standard algorithms, and bone structure observation using bone algorithms to obtain high-quality, standardized axial images.
Study NCT04954417 — intervention group
Intervention type: OTHER
Intervention: Deep learning
Description: We will use a conditional generation adversarial network-based image mapping technique to train the mapping model between MSCT images and Micro-CT images, find the correspondence between the image information contained in each of MSCT and Micro-CT, and finally obtain high-resolution micro-CT-like images.
Study NCT04954417 — intervention group
Intervention type: PROCEDURE
Intervention: Bio-mechanical testing
Description: we will cut a standardized cubic sample from the vertebral cancellous bone , obtain the bio-mechanical performance index of this cancellous bone sample by mechanical experiments, and analyze the correlation between bone structure of Micro-CT-like images and bio-mechanical index.
Study NCT05320510 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Se-yeast
Description: The participants will be asked to take Se-yeast tablet. The intervention period is about 3 months. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
Study NCT05320510 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The participants will be asked to take placebo-yeast tablet. The intervention period is about 3 months. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
Study NCT06018662 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A medication management mobile application
Description: A mobile application to select the most appropriate drugs for anesthetics, antimicrobials and analgesics, in addition to dose calculations
Study NCT05702385 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Materials for a new diagnostic test
Description: These materials detail what the test does, how it is used, the validity and specifications of the test, and how to read its test report.
Study NCT05029453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: In experimental group, the drug used with apatinib and chemotherapy.
Study NCT06379542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XC8
Description: 40 mg/day or 80 mg/day for 7-14 days
Study NCT06379542 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 tablets/day for 7-14 days
Study NCT06530355 — intervention group
Intervention type: OTHER
Intervention: The same evaluation methods were used for both groups.
Description: No treatment applied to participants and same evaluation methods used in all athletes.
Study NCT05761470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab at a fixed dose of 200mg via IV infusion on Days 1 each 21-day cycle.~Fluzoparibat at a fixed dose of 100mg BID, each 21-day cycle. Nab-paclitaxel at a fixed dose of 260 milligrams via intravenous (IV) infusion on Days 1 each 21-day cycle.
Study NCT05761470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: Fluzoparib
Study NCT05761470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel
Study NCT06334705 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: blood test, food collection, hair collection, calcium scan, etc.
Description: everything is specified during the phone call and in the consent form to be signed
Study NCT05180890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danavorexton
Description: Danavorexton intravenous infusion.
Study NCT05180890 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intravenous infusion.
Study NCT05356650 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan Mobilization
Description: The patient will be in a prone position. With one hand, the physiotherapist will fix the sacrum and place the fingers of her other hand under the anterior superior iliac spine. The therapist then pull the ilium on the sacrum and will instruct the patient to do press-ups. Treatment will be given with frequency of 3 sets with 10 repetitions on sacroiliac joint 3 times a week for 6 weeks
Study NCT05356650 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF
Description: PNF stretching will be performed using contract-relax techniques of agonists in supine, prone and side-lying. Contract-relax will be applied with a 6-second contraction with 80% force of the maximal isometric contraction on the muscles (iliopsoas, hamstrings and gluteal muscles) and will be followed by a 15-second passive static stretching in the opposite direction of that muscles. Three sets of stretching of each muscle will be performed for each position with the frequency of 3 times a week for 6 weeks.~Patient will be in supine, prone, side lying. Both groups will receive a baseline treatment (Moist Heat Pack for 10 minutes and 10 minutes of Ultrasound (0.75 MHz, continuous wave)
Study NCT06226337 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: listen music
Description: During hysterosalpingography, women were listened to the Acemaşiran maqam as music via MP4 players and headphones.
Study NCT05164198 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab and its biosimilars
Description: 1. Active substance: Adalimumab~2. Pharmaceutical form: Prefilled syringe~3. Concentration: 100mg/mL~4. Route of administration: Subcutaneous injection
Study NCT05164198 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab and its biosimilars
Description: 1. Active substance: Adalimumab~2. Pharmaceutical form: Prefilled syringe~3. Concentration: 100mg/mL~4. Route of administration: Subcutaneous injection
Study NCT05164198 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Biological: Etanercept and its biosimilars
Description: 1. Active substance: Etanercept~2. Pharmaceutical form: Prefilled syringe~3. Concentration: 50mg/mL~4. Route of administration: Subcutaneous injection
Study NCT05164198 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological: Etanercept and its biosimilars
Description: 1. Active substance: Etanercept~2. Pharmaceutical form: Prefilled syringe~3. Concentration: 50mg/mL~4. Route of administration: Subcutaneous injection
Study NCT05164198 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Golimumab
Description: 1. Active substance: Adalimumab~2. Pharmaceutical form: Prefilled syringe~3. Concentration: 100mg/mL~4. Route of administration: Subcutaneous injection
Study NCT05164198 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: 1. Active substance: Adalimumab~2. Pharmaceutical form: Prefilled syringe~3. Concentration: 100mg/mL~4. Route of administration: Subcutaneous injection
Study NCT05164198 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab biosimilar
Description: 1. Active substance: Infliximab~2. Pharmaceutical form: Prefilled syringe~3. Concentration: 120mg/mL~4. Route of administration: Subcutaneous injection
Study NCT05164198 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infliximab biosimilar
Description: 1. Active substance: Infliximab~2. Pharmaceutical form: Prefilled syringe~3. Concentration: 120mg/mL~4. Route of administration: Subcutaneous injection
Study NCT05646576 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Palliative Care
Description: * Palliative care (PC) intervention tailored to ACT recipients and addressing multiple PC domains with the input of ACT clinical experts, PC clinicians, and patients and caregivers.~* Domains discussed include therapeutic relationship, symptom management, prognostic awareness and illness understanding, coping with illness, treatment decision-making, EOL care.~* The palliative care intervention will be refined for the randomized control trial based on the feedback from the open pilot.
Study NCT05646576 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Standard care for ACT per the treating team.
Study NCT05962190 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: High fat (\~60% of total energy intake) diet enriched with either SFA or UFA
Study NCT04876131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzylpenicillin - single dose
Description: Participants will receive a single dose of IV antibiotic (benzylpenicillin).~Benzylpenicillin dosing: 1 month - 18 years, IV or Intramuscular (IM) 30 mg/kg (maximum 1.2 g) every 6 hours.
Study NCT04876131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzylpenicillin - three days
Description: Participants will receive three days of this IV antibiotic (benzylpenicillin).~Benzylpenicillin dosing: 1 month - 18 years, IV or Intramuscular (IM) 30 mg/kg (maximum 1.2 g) every 6 hours. For severe infections, use up to 60 mg/kg (maximum 2.4 g) every 4-6 hours.
Study NCT04876131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentamicin - single dose
Description: Participants will receive a single dose of IV antibiotic (gentamicin).~Gentamicin dosing: Children ≤10 years old: 7.5 mg/kg (maximum dose 320 mg) Children >10 years old: 6-7 mg/kg (maximum dose 560 mg)
Study NCT04876131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gentamicin - three days
Description: Participants will receive three days of this IV antibiotic (gentamicin).~Gentamicin dosing: Children ≤10 years old: 7.5 mg/kg (maximum dose 320 mg) Children >10 years old: 6-7 mg/kg (maximum dose 560 mg)
Study NCT04876131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefalexin - post single dose of IV antibiotics for the remaining two days
Description: Oral antibiotic will be as per local guidelines. i.e. Cefalexin 25mg/kg (maximum dosage 500mg) 4 times a day or 33mg/kg (maximum dosage 500mg) 3 times a day
Study NCT06012981 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT
Description: The treatment is based on a variant of CBT, as briefly referred to before, ACT. In short, the treatment consists of identifying central and important areas of life, and how to approach these even though you are also struggling with persistent and challenging problems. In this study, the treatment intervention is flexibly constructed, focusing on several central principles based on ACT. These can be applied during one or numerous sessions.~The intervention is a flexible application of clinical functional analysis, as well as a couple of selected interventions which, in terms of experience and in previous studies, have been shown to work well for the current group (24-hour psychiatric patients with complex problems) and which are individually adaptable to the nature of the problem and degree.
Study NCT06358248 — intervention group
Intervention type: DEVICE
Intervention: Physician-modification of Valiant Captivia Endograft (Medtronic, Minneapolis, MN-USA).
Description: On a sterile back-table a Valiant Captivia thoracic graft is deployed. A dotted line is drawn to mark the graft anterior 0° degree, and fabric holes are performed with cautery in the desired position. The fenestrations need to be 6x6 mm for the renals and 8x8 mm for superior mesenteric artery (SMA) and celiac trunk (CT), and are reinforced with the tip of a 0.018 guidewire through a continuous 5-0 locking suture.~A posterior constraining wire is created to reduce the diameter of the graft by 20-30%, in order to allow rotation during the deployment phase. The four 8 markers on the top of the graft are carefully removed with a scalpel; one of these is modified as an S and re-sutured on the anterior aspect at 0 degree position, with a 5-0 prolene continuous suture. This S marker will allow anteroposterior graft orientation. Finally, the graft is re-sheathed and deployed.
Study NCT04964349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids Acting Locally
Description: topical application of jessener solution
Study NCT05235282 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IQoro
Description: An acrylic mouth guard with a pulling loop. The mouth guard is placed in the mouth of the patient on the outside of the teeth. The therapist pulls the loop in different directions and the patient try to close his/her mouth on the mouth guard to keep it inside the mouth.
Study NCT05235282 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care for swallowing function
Description: Cuff deflation, speaking valve, masako exercises, shaker exercises, coughing, stimulation of the oral cavity, neuromuscular electrical stimulation, postural control
Study NCT05235282 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care for swallowing function
Description: Cuff deflation, speaking valve, masako exercises, shaker exercises, coughing, stimulation of the oral cavity, neuromuscular electrical stimulation, postural control